Neoadjuvant Therapy Before Radical Prostatectomy For Clinical T3/T4 Carcinoma of the Prostate: 5-Year Followup, Phase II Southwest Oncology Group Study 9109

Powell, Isaac J.; Tangen, Catherine M.; Miller, Gary J.; Lowe, Bruce A.; Haas, Gabriel P.; Carroll, Peter R.; Osswald, Michael B.; White, Ralph deVere; Thompson, Ian M.; Crawford, E. David

doi:10.1016/s0022-5347(05)64285-1

Cited by 59 publications

(22 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Good evidence moreover supports the use of NADT in association with EBRT in high risk disease, 29,30 and investigators have recently reported favorable experience using NADT with RP for locally advanced disease. 31 Other recent studies in patients with more favorable risk factors, in contrast, have demonstrated that NADT prior to RP does not improve outcomes. 32,33 The benefit for NADT prior to EBRT, likewise, appears to be restricted to patients with higher risk tumors.…”

Section: Discussionmentioning

confidence: 97%

The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management

Cooperberg

Lubeck

Meng

et al. 2004

JCO

Self Cite

510

319

View full text Add to dashboard Cite

Purpose-Early intervention for prostate cancer is associated with excellent long-term survival, but many affected men, especially those with low-risk disease characteristics, might not suffer adverse impact to quantity or quality of life were treatment deferred. We sought to characterize temporal trends in clinical presentation and primary disease management among patients with low-risk prostate cancer.Methods-Data were abstracted from CaPSURE, a disease registry of 8685 men with various stages of prostate cancer. 2078 men were included who were diagnosed between 1989 and 2001 and had a serum prostate specific antigen (PSA) ≤ 10 ng/ml, Gleason sum ≤ 6, and clinical Tstage ≤ 2a. Trends in risk distribution, tumor characteristics, and primary treatment were evaluated.

show abstract

Section: Discussionmentioning

confidence: 97%

The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management

Cooperberg

Lubeck

Meng

et al. 2004

JCO

Self Cite

510

319

View full text Add to dashboard Cite

show abstract

“…Hormone naive TURP specimens were derived from patients who were diagnosed with prostate cancer by TURP, having high grade (Gleason 8 or higher) and volume of disease. A separate group of radical prostatectomy that had previously undergone neoadjuvant therapy (Meyer et al 1999, Powell et al 2002 for 3 months prior to radical prostatectomy was also added to the prostate cancer tissue microarray as a neoadjuvant group. Due to the heterogeneous nature of prostate cancer, each case is represented by four 0·6 mm cores.…”

Section: Prostate Tissue Specimens and Pathological Evaluationmentioning

confidence: 99%

Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland

Gao¹,

Wang²,

Lee³

et al. 2006

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Androgen receptor (AR) is a ligand-activated transcription factor that mediates the action of androgens and is essential for the growth, function, and cell differentiation of the prostate gland. Here, we demonstrated that the prostate apoptosis response factor-4 (par-4) functions as a novel AR coactivator. Par-4 physically interacted with the DNA-binding domain of AR, enhanced AR interaction with DNA, and increased AR-dependent transcription. Par-4 enhanced the c-FLIP promoter activity and was recruited on to the c-FLIP gene in the presence of androgens, and the dominant-negative par-4 decreased c-FLIP expression. These results suggest that, in addition to its proapoptotic function, par-4 acts as a novel transcription cofactor for AR to target c-FLIP gene expression. In addition, we demonstrated that loss of c-FLIP expression was essential for castration-induced apoptosis in the prostate gland and that enhanced c-FLIP expression was associated with prostate cancer progression to the androgen-resistant stage. Our data shed light on a transcription-mediated mechanism for the effects of the AR pathway on cell survival and apoptosis.

show abstract

“…However, because of errors in clinical staging, specimens of 30%-40% of localized prostate patients who underwent RP showed extraprostatic involvement. [11,12] In addition, 35% patients develop BCR within 10 years following the operation. [13][14][15] Because of the superior sensitivity of PSA, recurrence of the disease can be diagnosed during the early term.…”

Section: Discussionmentioning

confidence: 99%

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy

Ün¹,

Türk²,

Koca³

et al. 2015

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: This study was conducted to research the factors determining biochemical recurrence (BCR) in low-risk localized prostate cancer patients who underwent radical prostatectomy (RP). Material and methods:We retrospectively analyzed the data of 504 patients who had undergone RP between 2003 and 2013 at our clinic. One hundred and fifty-two patients who underwent RP for low-risk prostate cancer were included in the study. Results:The mean follow-up period for patients was 58.7 (21-229) months. The mean age of the patients was 63.7±7.2 years (49-79). The mean prostate specific antigen (PSA) value was 5.25±4.22 ng/mL (3.58-9.45). The BCR rate after the operation was 25% (38/152). In the univariate analysis, recurrence determining factors were shown to include extracapsular involvement (ECI) (p= 0.004), capsular invasion (CI) (p= 0.001), age (p= 0.014), and tumor size (p= 0.006). However, only CI was found to be significant in multivariate analysis (p= 0.001). Conclusion:Capsular invasion is an independent risk factor in low-risk prostate cancer patients who underwent RP for BCR.

show abstract

Neoadjuvant Therapy Before Radical Prostatectomy For Clinical T3/T4 Carcinoma of the Prostate: 5-Year Followup, Phase II Southwest Oncology Group Study 9109

Cited by 59 publications

References 7 publications

The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management

The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management

Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy

Contact Info

Product

Resources

About